

## REMARKS

The Examiner, in the above-identified Office Action/Restriction Requirement, mailed July 25, 2006, has issued a Restriction Requirement, presented on pages 2-6 of the Action, asserting under 35 USC 121 that the pending claims constitute 2 distinct inventions. The Examiner asserts that the inventions constitute different inventions, and that the search of the multiple groups would impose a serious burden on the Examiner.

Applicants elect with traverse Group I, as remaining claims 1, 2, 3, 5, 7, 8, 9, 10, 11, and 22 as amended, and new dependent claims 25-32 for amended claim 22, corresponding to amended dependent claims 2, 3, 5, 7, 8, 9, 10 and 11, drawn to inhibition of IL-13 in patients having asthma related conditions, and have canceled claims 4, 6, and 12-21, without prejudice to filing divisional or continuation application thereon, as fully supported by the specification as filed.

Applicants also make the following species elections.

- (A) Applicants elect fragment 30-40 of SEQ ID NO:1 as recited in claims 1 and 22
- (B) Applicants have canceled claim 13 rendering this election moot.
- (C) Applicants elect bronchial inflammation.

Applicants reserve their rights to file or add additional claims and species according to the results of the search and examination by the Examiner, as well as filing divisional or continuation applications directed the subject matter of the cancelled claims.

If any fees are due in connection with the filing of this Response, authorization is hereby given to charge the amount of such fee to Deposit Account No. 10-0750/CEN0291CIP1/GKT in the name of Johnson & Johnson.

Respectfully submitted,

/Guy Kevin Townsend/

Guy Kevin Townsend  
Attorney for Applicant(s)  
Registration No. 34,033

**Johnson & Johnson**  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
732.524.2517  
**Dated:** August 24, 2006